Theracryf (TCF)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

0.82p
   
  • Change Today:
    -0.030p
  • 52 Week High: 3.40p
  • 52 Week Low: 0.68p
  • Currency: UK Pounds
  • Shares Issued: 427.35m
  • Volume: 0
  • Market Cap: £3.50m

Deal with Barclays    Trade now with Barclays Stockbrokers

Theracryf Overview

TheraCryf is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. The Company’s clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos’ neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.

1 Day Chart

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -892.5% n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 9.1 n/a
Pr/Book 1.6  
Latest F'cast
Revenue -9.1% n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Theracryf Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Mar-20 n/a (3.17) (2.07)p n/a n/a n/a n/a 0.0%
31-Mar-21 0.19 (3.21) (1.82)p n/a n/a n/a n/a 0.0%
31-Mar-22 n/a (3.17) (0.99)p n/a n/a n/a n/a 0.0%
31-Mar-23 0.44 (5.01) 1.47p 2.5 n/a n/a n/a 0.0%
31-Mar-24 0.40 (3.57) (1.14)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Theracryf Company Announcements

Annual Financial Report and Notice of AGM 21-Jun-2024 09:00 RNS
Holding(s) in Company 13-Jun-2024 15:14 RNS
Holding(s) in Company 04-Jun-2024 15:04 RNS

Latest Theracryf Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

Theracryf Market Data

Currency UK Pounds
Share Price 0.82p
Change Today -0.030p
% Change -3.53 %
52 Week High 3.40p
52 Week Low 0.68p
Volume 0
Shares Issued 427.35m
Market Cap £3.50m

Theracryf Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
37.24% below the market average37.24% below the market average37.24% below the market average37.24% below the market average37.24% below the market average
49.02% above the sector average49.02% above the sector average49.02% above the sector average49.02% above the sector average49.02% above the sector average
Price Trend
91.85% below the market average91.85% below the market average91.85% below the market average91.85% below the market average91.85% below the market average
69.81% below the sector average69.81% below the sector average69.81% below the sector average69.81% below the sector average69.81% below the sector average
Income Not Available
Growth
18.18% below the market average18.18% below the market average18.18% below the market average18.18% below the market average18.18% below the market average
39.39% below the sector average39.39% below the sector average39.39% below the sector average39.39% below the sector average39.39% below the sector average

Theracryf Dividends

No dividends found

Trades for --2024

Time Volume / Share Price
0 @ 0.000p

Theracryf Key Personnel

CEO Huw Jones
CFO Toni Hänninen

Top of Page